As GLP-1s become more available and affordable, beauty is reckoning with their impact and adjusting playbooks accordingly.

Semaglutides like Ozempic, Wegovy and Zepbound have taken over the market. A new deal forged by the Trump administration is set to lower costs in the US, while manufacturers are exploring next-generation GLP-1 delivery systems. Eli Lilly is developing Orforglipron, a pill alternative to the injectable weight-loss drug, Iconovo is experimenting with intranasal semaglutides and microneedle patches, while Vivani Medical is developing year-long implants for sustained release.

Already, up to 12% of Americans are estimated to be GLP-1 users, according to research firm Rand, a percentage expected to increase as new formats evolve and more research on the efficacy — as well

See Full Page